MEI Pharma, Inc. (MEIP)
NASDAQ: MEIP · Real-Time Price · USD
2.500
+0.040 (1.63%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors.
The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.
MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
MEI Pharma, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Dec 19, 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Justin File |
Contact Details
Address: 9920 Pacific Heights Blvd., Suite 150 San Diego, California 92121 United States | |
| Phone | 858 369 7100 |
| Website | meipharma.com |
Stock Details
| Ticker Symbol | MEIP |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001262104 |
| CUSIP Number | 55279B202 |
| ISIN Number | US55279B3015 |
| Employer ID | 51-0407811 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yomara Gomez-Naiden | Senior Vice President of Operations and Quality |
| Nicole Chyoko Iida | Vice President of Legal Affairs |
| Anne Frese | Chief People Officer |
| Dr. Robert D. Mass | Strategic Advisor |
| David A. Walsey J.D., L.L.M. | Senior Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | ARS | Filing |
| Dec 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 20, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Oct 25, 2024 | 8-K | Current Report |
| Sep 19, 2024 | 10-K | Annual Report |
| Sep 19, 2024 | 8-K | Current Report |
| Aug 2, 2024 | 8-K | Current Report |